NCCN Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology

The rapid integration of new therapeutic agents into treatment for various types of cancer can be challenging for clinicians.  Cancer treatment is constantly evolving, and it is crucial for health care professionals to stay up to date with the latest developments in the field. Pharmacists are critical to the education of the interprofessional oncology care team about the actions and potential adverse events associated with new and existing therapeutic options, as well as patient safety and education, quality of care, and subsequent monitoring and management of treatment-related toxicities.  

This webinar series, facilitated by expert oncology pharmacists, will provide the interprofessional oncology care team with up-to-date knowledge and skills related to the treatment and management of patients with cancer and highlight the importance of interprofessional care and collaboration between health care providers to ensure the best possible outcomes for patients with cancer.

Target Audience

This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates/assistants and other health care professionals who treat patients with cancer.

Learning Objectives

Following this activity series, participants should be able to:

  • Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
  • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
  • Communicate the importance of an interprofessional approach and improve the collaborative performance of the oncology care team in the management of patients with cancer.
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Genentech, a member of the Roche Group
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Novartis
Course summary
Course opens: 
01/07/2025
Course expires: 
12/31/2025
Cost:
$0.00

Beyond the Package Insert: Appropriate Interpretation of Testing Results for Targeted Therapy Selection
Friday, February 28, 2025 • 1:00 – 2:00 PM EST
Mya Tran, PharmD, BCOP, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

 

WEBINAR TIMES ARE EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).
Access to participate in selected sessions is through Zoom on the day of each scheduled program.

    The most recent recorded webcasts from this series will be listed below. Recordings from the previous series can be found here.

    NCCN Continuing Education Disclosure Policy
    It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

    In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

    Definitions  

    Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

    Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

    Faculty Disclaimers  

    All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

    Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

    Full disclosure of faculty relationships will be made prior to the activity.

    In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Physicians
    NCCN designates each live activity in this series for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses
    NCCN designates each educational activity in this series for a maximum of 1.0 contact hour.

    Pharmacists
    NCCN designates each application-based continuing education activity in this series for 1.0 contact hour (0.10 CEUs) of continuing education credit. 

    PAs
    NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Each activity in this series is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

     
    Status
    Price
    Title
    Locked
    $0.00Included
    NCCN Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology
    Please login or register to take this course.
    Locked
    $0.00Included
    Optimizing Patient Outcomes - Beyond the Package Insert: Appropriate Interpretation of Testing Results for Targeted Therapy Selection
    Please login or register to take this course.

    Price

    Cost:
    $0.00
    Please login or register to take this course.

    NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
    NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

    To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

    Required Hardware/software

    To complete this activity, users will need:

    • A device with an Internet connection and sound playback capability
      • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
      • Internet Explorer is no longer supported
    • Adobe Reader or other PDF reader software for certificate viewing/printing